Key Points
- Director Isaac Barchas sold 62,291 Immunome shares for approximately $1.63 million at an average price of $26.23, reducing his direct holdings by 40.32% to 92,211 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Immunome shares opened at $27.99, up 6.6%, near their 12-month high of $28.04. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $34.64.
- The company reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss; analysts expect a full-year loss of approximately $2.06 per share.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Isaac Barchas sold 10,125 shares of the firm's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $26.07, for a total value of $263,958.75. Following the sale, the director directly owned 62,291 shares of the company's stock, valued at $1,623,926.37. The trade was a 13.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Isaac Barchas also recently made the following trade(s):
- On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The shares were sold at an average price of $27.25, for a total transaction of $301,058.00.
- On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93.
- On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $397,362.88.
- On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $543,090.40.
- On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
- On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total transaction of $2,003,396.34.
- On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
- On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.
Immunome Stock Performance
NASDAQ:IMNM opened at $27.99 on Thursday. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $28.04. The company has a 50 day moving average price of $21.89 and a 200 day moving average price of $22.20. The stock has a market capitalization of $3.17 billion, a P/E ratio of -11.06 and a beta of 2.08.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). Research analysts forecast that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.
Key Immunome News
Here are the key news stories impacting Immunome this week:
- Positive Sentiment: Truist’s higher price target and Buy rating likely supported investor enthusiasm and helped drive IMNM toward a fresh 52-week high. Truist price target update
- Positive Sentiment: Immunome reported second-quarter 2026 results and provided a business update. Investors continue to focus on the company’s clinical pipeline and progress in its antibody-based oncology and infectious-disease programs, which are central to its valuation. Immunome second-quarter 2026 results and business update
- Neutral Sentiment: Director Isaac Barchas sold 98,712 shares from August 10 through August 12 for approximately $2.6 million, reducing his direct ownership to 92,211 shares. The sales occurred under a pre-arranged Rule 10b5-1 plan, making them less conclusive as a signal of management’s current outlook. Immunome director insider sales SEC filing
- Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss estimate of $0.51. The miss highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome quarterly earnings release
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Citigroup reissued a "buy" rating on shares of Immunome in a research note on Thursday, July 9th. HC Wainwright reaffirmed a "buy" rating on shares of Immunome in a research report on Thursday, July 9th. Wall Street Zen lowered shares of Immunome from a "hold" rating to a "sell" rating in a research note on Saturday, May 30th. Truist Financial increased their price target on shares of Immunome from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a research report on Friday, July 17th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome has a consensus rating of "Moderate Buy" and a consensus target price of $34.64.
Get Our Latest Stock Report on Immunome
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Immunome during the 2nd quarter worth approximately $186,588,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company's stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company's stock worth $61,341,000 after purchasing an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA lifted its position in shares of Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company's stock worth $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Immunome during the fourth quarter worth $30,710,000. Hedge funds and other institutional investors own 44.58% of the company's stock.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
